Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

5924 - Deprescribing Potentially Inappropriate Medication in Cancer Patients


28 Sep 2019


Poster Display session 1


End-of-Life Care

Tumour Site


Simon Reuter


Annals of Oncology (2019) 30 (suppl_5): v661-v666. 10.1093/annonc/mdz261


S.B. Reuter1, T.S. Petersen2

Author affiliations

  • 1 Department Of Clinical Pharmacology, Bispebjerg Hospital, 2400 - Copenhagen/DK
  • 2 Department Of Clinical Pharmacology, Bispebjerg Hospital, 2400 NV - Copenhagen/DK


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5924


Due to their advanced age many cancer patients with unfavorable prognosis suffer from comorbidities, and thus the risk of consuming potentially inappropriate medication (PIM). It is vital to deprescribe drugs with potential harmful effects or no short-term benefit for lowering pill.

Hence, we examined the degree of deprescription of potentially inappropriate medication (PIM) in patients suffering from cancer.


Retrospective, register-based study of all patients with newly diagnosed breast, prostate, pancreatic, and lung cancer, diagnosed at a hospital in the Capital Region of Denmark (1.8 million inhabitants) from 2012-2014. Patients with insufficient staging information or other malignancy except non-melanoma skin-cancer were excluded. Information about medication, comorbidity and mortality was extracted from the electronic health records.

PIM were defined as: acetylsalicylic acid, calcium channel blockers, statins, thiazides, and bisphosphonates. The study was approved by the Danish Patient Safety Authority (No. 3-3013-1884/1/) and the Danish Data Protection Agency (No. BFH-2016-058).




Breast (n = 3,959)/prostate cancer (n = 3,535) (total n = 7,494)Lung (n = 2,824)/pancreatic cancer (n = 617) (n = 3,441)
Gender (Women)52%50%
Age mean (sd)65 (12)70 (10)
1-year Survival97%46%
Metastatic disease6.7%52%
Diabetes4.0 %9.7 %
Hypertension12 %23 %
Atrial fibrillation4.7 %8.7 %
Ischemic heart disease6.4 %11.6 %
Heart failure2.2 %5.6 %
Ischemic stroke1.5 %2.8 %
Medication1-year deprescription/total treated§
Acetylsalicylic acid250/1,443 (17%)398/928 (43%)
Calcium channel blockers135/1,048 (13%)284/659 (43%)
Statins187/1,769 (11%)501/1,066 (47%)
Thiazide diuretics175/954 (18%)259/534 (49%)
Bisphosphonates26/319 (8.2%)64/171 (37%)

Deprescribed during the first year after cancer-diagnosis/total number of patients treated

(Patients not surviving 1 year and treatment continuing until death does not count towards deprescribed)


Our findings show that oncologists and physicians have a rational approach to deprescription in patients suffering from cancer with short-term (pancreatic and lung cancer) respectively long-term (breast and prostate cancer) survival rates. However, several patients were continuing potential inappropriate medications in the terminal stage of cancer.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.